A curated library of guides, compliance knowledge, and operational insights to help pharmaceutical teams navigate Open Payments reporting, manage HCP events, and streamline field workflows.
On September 9, 2026, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBBRead more
On October 16, 2026, the U.S. Food and Drug Administration, in partnership with the Reagan-Udall Foundation for the FDA (Foundation), will convene a hybrid meeting to explore the patient voice in rare disease medical product development (biologic, drug, and device).Read more
A user fee program for nonprescription (over-the-counter or OTC) monograph drugs would be a potential funding mechanism to supplement congressional non user-fee appropriations.Read more
